Mood and anxiety disorders in patients with myasthenia gravis: Aetiology, diagnosis and treatment

CNS Drugs

Volumn 21, Issue 6, 2007, Pages 473-481

  Kulaksizoglu, Isin Baral ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHLORPROMAZINE; CITALOPRAM; CORTICOSTEROID DERIVATIVE; DIAZEPAM; DROPERIDOL; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; LITHIUM CARBONATE; MOOD STABILIZER; PHENYTOIN; PREDNISOLONE; PREDNISONE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

ANXIETY DISORDER; BIPOLAR DISORDER; CATATONIA; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIFFERENTIAL DIAGNOSIS; ELECTROCONVULSIVE THERAPY; EPILEPSY; EUPHORIA; HUMAN; HYPOMANIA; MANIA; MENTAL DISEASE; MENTAL STRESS; MOOD DISORDER; MYASTHENIA GRAVIS; NEUROMUSCULAR DISEASE; NEUROMUSCULAR JUNCTION DISORDER; PARENT COUNSELING; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; WEAKNESS;

ANXIETY DISORDERS; CHRONIC DISEASE; HUMANS; MOOD DISORDERS; MYASTHENIA GRAVIS; QUALITY OF LIFE;

EID: 34249775815     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200721060-00004     Document Type: Review

References (68)

1. Kanner A. Should neurologists be trained to recognize and treat co-morbid depression of neurological disorders? Yes. Epilepsy Behav 2005; 6: 303-11
2. Cummings J, Mega M, editors. Disturbances of mood and affect in neuropsychiatry and behavioral neuroscience. Oxford: Oxford University Press, 2003: 200-28
3. Cummings J, Mega M, editors. Disturbances of mood and affect in neuropsychiatry and behavioral neuroscience. Oxford: Oxford University Press, 2003: 67-9
4. Kulaksizoglu IB, Gürvit H, Polat A, et al. Unrecognized depression in community-dwelling elderly persons in Istanbul. Int Psychogeriatr 2005; 17 (2): 303-12
5. Kanner A, Barri JJ. The impact of mood disorders in neurological diseases: should neurologists be concerned? Epilepsy Behav 2003; 4: 3-13
6. Kupfer DJ, Frank E. Comorbidity in depression. Acta Psychiatr Scand 2003; 418: 57-60
7. Engel AG. Acquired autoimmune myasthenia gravis. In: Engel AG, Franzini-Armstrong C, editors. Myology. New York: MacGraw-Hill, 1994: 1769-97
8. MacDonald BK, Cockerell OC, Sander JW, et al. The incidence and life-time prevalence of neurological disorders in a prosodes. spective community-based study in UK. Brain 2000; 123: 665-76
9. Grob D. Clinical manifestations of myasthenia gravis. In: Albuquerque E, Eldefrawi A, editors. Myasthenia gravis. New York: Chapman Hall, 1985: 319-45
10. Seybold M. Diagnosis of myasthenia gravis. In: Engel GA, editor. Myasthenia gravis and myasthenic disorders. Contemporary neurology series. Oxford: Oxford University Press, 1999: 146-60
11. Emery EJ, Szymanski HV. Psychological symptoms preceding diagnosed myasthenia gravis. Psychosomatic 1981; 22 (11): 993-5
12. Pourmand R. Myasthenia gravis. Dis Mon 1997 Feb; 43 (2): 65-109
13. Rohr W. Myasthenia gravis in the frontier of psychiatric diagnosis. Psychiatr Prax 1992 Sep; (19) 5: 157-63
14. Perez-Nellar J, Rodriguez A. False negatives in the diagnosis of myasthenia gravis. Rev Neurol 2000; 30 (8): 712-5
15. Nicholson GA, Wilby J, Tennant C. Myasthenia gravis: the problem of a 'psychiatric' misdiagnosis. Med J Aust 1986 Jun 9; 144 (12): 632-8
16. Cassem NH. Depression. In: Hackett TP, Cassem NH, editors. Massachusetts General Hospital handbook of general hospital psychiatry. Chicago (IL): Year Book Medical Publishers, 1978: 227-61
17. Paul RH, Cohen RA, Goldstein JM, et al. Severity of self-evaluative and vegetative symptoms of depression in myasthenia gravis. J Neuropsychiatry Clin Neurosci 2000; 12 (4): 499-501
18. Bergonzi P, Mazza S, Mennuni G, et al. Central nervous system involvement in myasthenia gravis. Ann N Y Acad Sci 1981; 377: 810-1
19. Papazian O. Rapid eye movement sleep alterations in myasthenia gravis. Neurology 1976; 26: 311-6
20. Tucker DM, Roeltgen DP, Wann PD, et al. Memory dysfunction in myasthenia gravis: evidence for central cholinergic effects. Neurology 1988; 38: 1173-7
21. Davidov-Lusting M, Klinghoffer V, Kaplan-Dinur A, et al. Memory abnormalities in myasthenia gravis: possible fatigue of central nervous system cholinergic circuits. Autoimmunity 1992; 14 (1): 85-6
22. Keesey J. Does myasthenia gravis affect the brain? J Neurological Sciences 1999; 170: 77-89
23. Groves M, Muskin P. Psychological responses to illness. In: Levenson J, editor. Textbook of psychosomatic medicine. Washington, DC: American Psychiatric Publishing, 2005: 67-87
24. Lipowski ZJ. Physical illness: the individual and coping process. Psychiatry Med 1970; 1: 91-102
25. Meyer E. Psychological disturbances in myasthenia gravis: a predictive study. Ann N Y Acad Sci 1966; 135: 417-23
26. Paradis C, Friedman S, Lazar RM, et al. Anxiety disorders in a neuromuscular a clinic. Am J Psychiatry 1993; 150 (7): 1102-4
27. Sneddon J. Myasthenia gravis: a study of social, medical and emotional problems in 26 patients. Lancet 1980: 526-8
28. MacKenzie KR, Martin MJ, Howard FM. Myasthenia gravis: psychiatric concomitants. Can Med Assoc J 1969; 100: 988-91
29. Marcus J. The interrelations of myasthenia gravis and psychiatric stress: presentation of a case. Israel Med J 1962; 21: 178-83
30. Oosterhuis HJ, Wilde GJS. Psychiatric aspects of myasthenia gravis. Psychiatr Neurol Neurochir 1964; 67: 484-96
31. Magni G, Micaglio G, Ceccato MB, et al. The role of life events in myasthenia gravis outcome: a one-year longitudinal study. Acta Neurol Scand 1989; 79: 288-91
32. Osserman KE, Genkins G. Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. Mt Sinai J Med 1971; 38: 497
33. Knieling J, Weiss H, Faller H, et al. Psychosocial causal attributions by myasthenia gravis patients: a longitudinal study of the significance of subjective illness theories after diagnosis and in the follow up. Psychother Psychosom Med Psychol 1995 Nov; 45 (11): 373-80
34. Knieling J, Weiss H, Faller H, et al. Follow up of myasthenia gravis: results of a longitudinal study of significance of psychosocial predictors. Nervenarzt 1998 Feb; 69 (2): 137-44
35. Magni G, Micaglio G, Lalli R, et al. Psychiatric disturbances associated with myasthenia gravis. Acta Psychiatr Scand 1988; 77: 443-5
36. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1980
37. Doering S, Henze T, Schüssler G. Coping with illness in myasthenia gravis. Nervenarzt 1993 Oct; 64 (10): 640-7
38. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed., rev. Washington, DC: American Psychiatric Association, 1987
39. World Health Organization. International classification of diseases. 10th ed. [online]. Available from URL: http:// www.who.int/classifications/apps/icd/ icd10online [Accessed 2007 May 17]
40. Eren I, Kulaksizoglu IB, Anuk D, et al. Post traumatic stress disorder in myasthenia gravis patients [abstract]. ESTSS 6th European Congress on Traumatic Stress; 1999 Jun 5-8: Istanbul, 147-8
41. Diagnostic and statistical manual of mental disorders. 4th ed, text rev. Washington, DC: American Psychiatric Association, 2000
42. Spitzer RL, Williams JB, Gibbon M, et al. The structured clinical interview for DSMIII-R (SCID-I): history, rationale, and description. Arch Gen Psychiatry 1992; 49: 624
43. Rohr W. Situational anxiety in myasthenia gravis. Psychother Psycosom Med Psychol 1993 Apr; 43 (3-4): 93-9
44. Paul R, Cohen R, Goldstein J, et al. Severity of mood, self evaluative and vegetative symptoms of depression in myasthenia gravis. J Neuropsychiatry Clin Neurosci 2000 Fall; 12 (4): 499-501
45. Paul R, Nash J, Cohen R. Quality of life and well-being of patients with myasthenia gravis. Muscle Nerve 2001 Apr; 24 (4): 512-6
46. Skeie O, Apolstolski S, Evoli A, et al. Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2006; 13 (7): 691-9
47. Brown ES, Suppes T. Mood symptoms during corticosteroid therapy: a review. Harvard Rev Psych 1998; 5: 239-46
48. Schmidt LA, Fox NA, Goldberg MC, et al. Effects of acute prednisone administration on memory, attention, and emotion in healthy human adults. Psychoneuroimmunol 1999; 24 (4): 461-83
49. Warrington TP, Botswick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc 2006; 81 (10): 1361-7
50. Schwartz ML, Cahill R. Psychopathology associated with myasthenia gravis and its treatment by psychotherapeutically oriented group counseling. J Chron Dis 1971; 24: 543-52
51. Kütemeyer M. Symptom changes during the psychotherapy of patients with myasthenia gravis. Psychother Psychosom 1979; 32: 279-86
52. Achiron A, Barak Y, Noy S, et al. Fluoxetine treatment for weight reduction in steroid-induced obesity: a pilot study in myasthenia gravis patients. Euro Psychopharmacol 1999; 9: 111-3
53. Kulaksizoglu IB, Aldemir D, Parman Y, et al. Citalopram treatment of depression in myasthenia gravis patients: an open study [abstract]. European Congress of Neuropsychopharmacology; 2005 Oct 22-26; Amsterdam, 426
54. Seybold M. Treatment of myasthenia gravis. In: Engel GA, editor. Myasthenia gravis and myasthenic disorders. Contemporary neurology series. Oxford: Oxford University Press, 1999: 167-201
55. Argov Z, Mastaglia FL. Disorders of neuromuscular transmission caused by drugs. N Engl J Med 1979; 30: 409-13
56. Howard JR. Adverse drug effects on neuromuscular transmission. Sem Neurol 1990; 10: 89-102
57. McQuillen MP, Gross M, Johns RJ. Chlorpromazine-induced weakness in myasthenia gravis. Arch Neurol 1963; 8: 286-90
58. Argov Z, Yaari Y. The action of chlorpromazine at an isolated cholinergic synapse. Brain Research 1979; 164: 227-36
59. Kramer M. Hypnotic medication in the treatment of chronic insomnia: non nocere! Doesn't anyone care? Sleep Med Rev 2000 Dec; 4 (6): 529-41
60. Neil JF, Himmelhoch JM, Licata SM. Emergence of myasthenia gravis during treatment with lithium carbonate. Arch Gen Psychiatry 1976; 33: 1090-2
61. Granacher RP. Neuromuscular problems associated with lithium. Am J Psychiatry 1977; 134: 702
62. Lipton ID. Myasthenia gravis unmasked by lithium carbonate [letter]. J Clin Psychopharmacol 1987; 7: 57
63. Vizi ES, Illes P, Ronai A, et al. The effect of lithium on acetylcholine release and synthesis. Neuropharmacology 1972; 11: 521-30
64. Hill GE, Wong KC, Hodges MR. Potentiation of succinylcholine neuromuscular blockage by lithium carbonate. Anesthesiology 1976; 44: 439-42
65. Lai CW, Leppik IE, Jenkins DC, et al. Epilepsy, myasthenia gravis, and effect of plasmapheresis on antiepileptic drug concentrations. Arch Neurol 1990 Jan; 47 (1): 66-8
66. Siddiqi ZA, Holt A, Ahmed SN. Effect of plasma exchange on carbamazepine levels in a patient with myasthenia gravis and epilepsy. Epilepsia 2005 Nov; 46 (11): 1841-2
67. Pande AC, Grunhaus LJ. ECT for depression in the presence of myasthenia gravis. Convuls Ther 1990; 6 (2): 172-5
68. Calarge CA, Crowe RR. Electroconvulsive therapy in myasthenia gravis. Ann Clin Psychiatry 2004 Oct-Dec; 16 (4): 225-7